Drug Persistency of Two Cholinesterase Inhibitors
- 1 January 2005
- journal article
- research article
- Published by Springer Nature in Drugs & Aging
- Vol. 22 (8) , 695-707
- https://doi.org/10.2165/00002512-200522080-00006
Abstract
To compare persistency rates and persistency days in patients with Alzheimer’s disease (AD) who initiated therapy with either rivastigmine or donepezil, and to identify factors influencing persistency in a real-world setting.Keywords
This publication has 44 references indexed in Scilit:
- No donepezil discontinuation effect in patients with Alzheimer's disease who were switched to rivastigmine after failing to benefit from donepezil treatmentCurrent Medical Research and Opinion, 2003
- Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease who Failed to Benefit from Treatment with DonepezilCurrent Medical Research and Opinion, 2002
- How Many Patients Complete an Adequate Trial of Donepezil?Alzheimer Disease & Associated Disorders, 2002
- Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classesClinical Therapeutics, 2001
- Predictors of Long-term Persistence on Statins in a Subsidized Clinical PopulationValue in Health, 2000
- Galantamine in ADNeurology, 2000
- Incontinence Drug Utilization Patterns in Québec, CanadaValue in Health, 1999
- Patient Noncompliance in the Managed Care SettingMedical Care, 1998
- A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's diseaseNeurology, 1998
- Risk factors for antihypertensive medication refill failure by patients under Medicaid managed careClinical Therapeutics, 1996